An investigational obesity drug by Eli Lilly could be fast-tracked for FDA approval under a new program. Speculation suggests orforglipron, the next-generation drug, may receive approval by the end of the year. The drug is a prime candidate for a fast-track review process recently launched by the FDA. Additionally, Eli Lilly plans to build a new $5 billion manufacturing facility in Virginia. The facility will focus on producing antibody-drug conjugates as part of the company’s aggressive capital expansion program. Analysts are optimistic about the potential of Eli Lilly’s stock, despite it not being on the Motley Fool’s list of top 10 stocks.

Read more at Nasdaq: Why Eli Lilly Stock Was a Winner Today